Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
SL0101 (SL 0101-1) a kaempferol glycoside isolated from the tropical plant F. refracta, is a novel, potent, cell-permeable, selective, reversible, ATP-competitive p90 Ribosomal S6 Kinase (RSK) inhibitor, with an IC50 of 89 nM. It causes a cell cycle block in the G1 phase and inhibits proliferation in the human breast cancer cell line MCF-7. While maintaining RSK specificity, SL0101 demonstrated improved in vitro biological stability. The creation of RSK inhibitors derived from SL0101 as anticancer agents ought to be made easier as a result of these findings.
Targets |
RSK1
|
---|---|
ln Vitro |
SL 0101-1 (SL0101) shows inhibition of proliferation in the human breast cancer cell line MCF-7 and results in a block in the G1 phase of the cell cycle[1].
|
References |
|
Molecular Formula |
C25H24O12
|
---|---|
Molecular Weight |
516.45086
|
Exact Mass |
516.13
|
Elemental Analysis |
C, 58.14; H, 4.68; O, 37.18
|
CAS # |
77307-50-7
|
Related CAS # |
77307-50-7
|
Appearance |
Solid powder
|
SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)OC(=O)C)OC(=O)C
|
InChi Key |
SXOZSDJHGMAEGZ-IGKKHSBFSA-N
|
InChi Code |
InChI=1S/C25H24O12/c1-10-21(34-11(2)26)24(35-12(3)27)20(32)25(33-10)37-23-19(31)18-16(30)8-15(29)9-17(18)36-22(23)13-4-6-14(28)7-5-13/h4-10,20-21,24-25,28-30,32H,1-3H3/t10-,20+,21-,24-,25-/m0/s1
|
Chemical Name |
[(2S,3S,4S,5R,6S)-4-acetyloxy-6-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-5-hydroxy-2-methyloxan-3-yl] acetate
|
Synonyms |
SL0101; SL0101; SL 0101; SL 0101-1; SL-0101-1; SL0101-1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9363 mL | 9.6815 mL | 19.3630 mL | |
5 mM | 0.3873 mL | 1.9363 mL | 3.8726 mL | |
10 mM | 0.1936 mL | 0.9681 mL | 1.9363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
SL0101 structure activity relationship studies. Chem Commun (Camb) . 2020 Mar 10;56(20):3058-3060. td> |
De novo approach to SL0101 cyclitol B-ring analogues. Chem Commun (Camb) . 2020 Mar 10;56(20):3058-3060. td> |